Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer. Result from the BEACON study have shown for the first time that a combination of three…
Read More
There were mixed results yesterday for dual-targeted therapy in HER2-amplified KRAS wild-type metastatic colorectal cancer (mCRC). The HERACLES-B trial (Abstract LBA35) did not reach its primary endpoint but encouraging objective response rates (ORRs) were reported…
Read More
With technological advances increasing the sensitivity and specificity of testing, liquid biopsies are fast making their mark as a diagnostic test for minimal residual disease (MRD), providing guidance on how to tailor treatment for early-stage…
Read More
At ESMO 2019, starting on Friday 27 September, promising results will be presented from some studies exploring the use of liquid biopsies in colorectal cancer (CRC), According to Daily Reporter Associate Editor Rodrigo Dienstmann, from…
Watch Here
